Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig

Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

Israel - Hebräisch - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - Hebräisch - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - Hebräisch - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - Hebräisch - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - Hebräisch - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - Hebräisch - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.